Dr. Sahil Bambroo

Kailash Hospital, Noida

Designation : Consultant Medical Oncologist

Speciality : Oncology (Cancer)

Areas of Expertise : Medical Oncology and Hematology, Stem Cell Transplantation

Qualificationnn : MD, DM

Normal OPD Premium OPD
MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY SUNDAY
N/A
N/A
6:00PM - 8:00PM
N/A
6:00PM - 8:00PM
N/A
N/A


    • Assistant Professor, Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Kochi (Sep 2019 - Sep 2020)
    • Clinical Observer, Henry Ford Health System, Detroit, Michigan, USA (May 2018)
    • Senior Resident, Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Kochi (Aug 2016 - Aug 2019)
    • Senior Resident, Internal Medicine, Pushpawati Singhania Research Institute, Sheikh Sarai, Delhi (Jun 2016 - Jul 2016)
    • Junior Resident, Department of General Medicine, Amrita Institute of Medical Sciences, Kochi (Jun 2013 - Jun 2016)

    • Delhi Medical Council - Reg No: 75935 
    • Travancore Cochin Medical Council – Reg No: 74646 
    • European Society of Medical Oncology – ID No: 408023 
    • European Society of Digestive Oncology
    • American Society of Clinical Oncology
    • Indian Society of Neuro-Oncology
    • Association of Physicians of India (Kerala Chapter)
    •  Observership in Henry Ford Health System, Detroit, Michigan, USA (May 2018) 
    • Second prize in Quiz, ONCOLOGY 2018 – Multidisciplinary management of common cancers (28-30 September 2018) 
    • Second prize in Poster – Analysis of EGFR 18, 19 and EGFR vIII over-expression in GBM and its prognostic significance – a single center experience, ISNOCON 2018, AIIMS Delhi (5-8 April 2018) 
    • Aswath Ram Jaya Nazir’ award for securing highest marks in Preventive and Social Medicine – 2009 
    • Certificate of Merit in Science and Social Science, HSC – CBSE 2003

    DM DISSERTATION - Analysis of BRAF V600E mutation in central nervous system in a 

    tertiary cancer centre in India.
    MD DISSERTATION – Association between HbA1c levels and Iron deficiency anemia in non-diabetic individuals.
     
    PUBLICATIONS
    Adherence to Antiemesis Guidelines in a Day Care Chemotherapy Unit:
    Experience from a Tertiary Care Centre;
    Indian Journal of Applied Research, Volume-9 | Issue-12 | December - 2019 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar 
     
    PRESENTATIONS 
    • Paper presentation - Analysis of BRAF V600E mutation in central nervous system in a tertiary cancer centre in India, ISNOCON, Bhopal (April 2019) 
    • Paper presentation – Renal Failure in Multiple Myeloma, A single centre experience, International Update on Plasma cell dyscrasias, KMIO, Bengaluru (11-12 February 2017)
    • Paper presentation – Rituximab - Bendamustine in treatment for Follicular Lymphoma, API Kerala Chapter, Quarterly Meeting, Perinthalmanna, Kerala (30 October 2016)
    • Paper presentation - A rare case of Vibrio vulnificus – Back water disease at Association of Physicians of India – Kerala Chapter, Thiruvananthapuram (9 March 2014 
    • Poster – Extranodal Lymphomas – A single centre experience : LYMPHOCON 2019 – An International update on Lymphomas, Department of Medical Oncology, Kidwai cancer Institute, Bengaluru and KMIO Medical Oncologists Alumni Association (12-13 January 2019)
    • Poster – Effect of Melphalan 200 v/s lesser doses in toxicities in patients with multiple myeloma undergoing single autologous stem cell transplantation: HAEMATOCON 2018, Indian Society of Haematology and Blood Transfusion (25-28 October, 2018)
    • Poster – Tamoxifen induced macular hole, Indian Breast cancer conference, Jaipur (5-7 October, 2018)
    • Poster – Analysis of EGFR 18, 19 and EGFR vIII over-expression in GBM and its prognostic significance – a single centre experience,ISNOCON 2018, AIIMS Delhi (5-8 April 2018)
    • Poster – Role of Vitamin C in treatment of Methemoglobinemia : a case series, at Amrita Hematocon 2014, AIMS, Kochi (18 January 2014)
    • Treatment of Breast cancer,
    • GI/GU malignancies,
    • Head and Neck cancers,
    • Prostate Cancer,
    • Lymphomas,
    • Leukemias and Multiple Myeloma;
    • Use of targeted therapy
    • novel agents in treatment of cancers,
    • Immunotherapy,
    • Palliative Care.

Get in Touch

Scroll to Top